{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:05:19Z","timestamp":1781845519193,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K17175"],"award-info":[{"award-number":["19K17175"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Interstitial pneumonia (IP) is a disease with a poor prognosis. In addition, IP patients are more likely to develop lung cancer. Since IP patients frequently develop toxicities during cancer treatment, minimally invasive cancer treatment is warranted for such patients to maintain their quality of life. This study retrospectively investigated the efficacy and safety of proton therapy (PT) for non-small cell lung cancer (NSCLC) in patients with IP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-nine NSCLC patients with IP were treated with PT between September 2013 and December 2019. The patients had stage IA to IIIB primary NSCLC. Ten of the 29 patients exhibited the usual interstitial pneumonia pattern. The prescribed dose was 66\u201374 Grays (relative biological effectiveness) in 10\u201337 fractions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median follow-up period was 21.1\u00a0months [interquartile range (IQR), 15.6\u201337.3] for all patients and 37.2\u00a0months (IQR, 24.0\u201349.9) for living patients. The median patient age was 77\u00a0years (IQR, 71\u201381). The median planning target volume was 112.0\u00a0ml (IQR, 56.1\u2013246.3). The 2-year local control, progression-free survival, and overall survival rates were 85% (95% confidence interval: 57\u201395), 30% (15\u201347), and 45% (26\u201362), respectively. According to the Common Terminology Criteria for Adverse Events (version 4.0), grade 3 acute radiation pneumonitis (RP) was observed in 1 patient. Two patients developed grade 3 late RP, but no other patients experienced serious toxicities. The patients\u2019 quality of life (European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 and SF-36) scores had not changed after 3\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>\ufeffPT may be a relatively safe treatment for NSCLC patients with IP, without deteriorating quality of life scores within 3\u00a0months.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13014-022-02027-0","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T09:02:55Z","timestamp":1647853375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of proton therapy for non-small cell lung cancer in patients with interstitial pneumonia"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7525-0288","authenticated-orcid":false,"given":"Shingo","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Toshito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Yamamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-etsu","family":"Mizoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Shibamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"2027_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1183\/09059180.00009113","volume":"23","author":"KM Antoniou","year":"2014","unstructured":"Antoniou KM, Margaritopoulos GA, Tomassetti S, Bonella F, Costabel U, Poletti V. Interstitial lung disease. Eur Respir Rev. 2014;23:40\u201354.","journal-title":"Eur Respir Rev"},{"key":"2027_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","volume":"389","author":"L Richeldi","year":"2017","unstructured":"Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389:1941\u201352.","journal-title":"Lancet"},{"key":"2027_CR3","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","volume":"378","author":"TE King","year":"2011","unstructured":"King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949\u201361.","journal-title":"Lancet"},{"key":"2027_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"key":"2027_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.resinv.2019.06.001","volume":"57","author":"T Ogura","year":"2019","unstructured":"Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, et al. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respir Investig. 2019;57:512\u201333.","journal-title":"Respir Investig"},{"key":"2027_CR6","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.jtcvs.2013.09.050","volume":"147","author":"T Sato","year":"2014","unstructured":"Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147:1604\u201311.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2027_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2169\/internalmedicine.3481-19","volume":"59","author":"E Ichihara","year":"2020","unstructured":"Ichihara E, Miyahara N, Maeda Y, Kiura K. Managing lung cancer with comorbid interstitial pneumonia. Intern Med. 2020;59:163\u20137.","journal-title":"Intern Med"},{"key":"2027_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4143\/crt.2014.180","volume":"47","author":"YH Lee","year":"2015","unstructured":"Lee YH, Kim YS, Lee SN, Lee HC, Oh SJ, Kim SJ, et al. Interstitial lung change in pre-radiation therapy computed tomography is a risk factor for severe radiation pneumonitis. Cancer Res Treat. 2015;47:676\u201386.","journal-title":"Cancer Res Treat"},{"key":"2027_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1748-717X-5-32","volume":"5","author":"H Yamashita","year":"2010","unstructured":"Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol. 2010;5:32.","journal-title":"Radiat Oncol"},{"key":"2027_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/jrr\/rru082","volume":"56","author":"T Ohno","year":"2014","unstructured":"Ohno T, Oshiro Y, Mizumoto M, Numajiri H, Ishikawa H, Okumura T, et al. Comparison of dose-volume histograms between proton beam and X-ray conformal radiotherapy for locally advanced non-small-cell lung cancer. J Radiat Res. 2014;56:128\u201333.","journal-title":"J Radiat Res"},{"key":"2027_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"WD Travis","year":"2002","unstructured":"Travis WD, King TE, Bateman ED, Lynch DA, Capron F, Center D, et al. American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277\u2013304.","journal-title":"Am J Respir Crit Care Med"},{"key":"2027_CR12","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers J, Richeldi L, Ryerson C, Lederer D, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44-68.","journal-title":"Am J Respir Crit Care Med"},{"key":"2027_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13014-018-1144-5","volume":"13","author":"K Nakajima","year":"2018","unstructured":"Nakajima K, Iwata H, Ogino H, Hattori Y, Hashimoto S, Toshito T, et al. Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer. Radiat Oncol. 2018;13:199.","journal-title":"Radiat Oncol"},{"key":"2027_CR14","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.ijrobp.2020.11.035","volume":"109","author":"H Iwata","year":"2020","unstructured":"Iwata H, Akita K, Yamaba Y, Kunii E, Takakuwa O, Yoshihara M, et al. Concurrent chemo-proton therapy using adaptive planning for unresectable stage 3 non-small cell lung cancer: a phase 2 study. Int J Radiat Oncol Biol Phys. 2020;109:1359\u201367.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2027_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s13246-016-0456-8","volume":"39","author":"T Toshito","year":"2016","unstructured":"Toshito T, Omachi C, Kibe Y, Sugai H, Hayashi K, Shibata H, et al. A proton therapy system in Nagoya Proton Therapy Center. Australas Phys Eng Sci Med. 2016;39:645\u201354.","journal-title":"Australas Phys Eng Sci Med"},{"key":"2027_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10147-017-1209-8","volume":"23","author":"K Nakajima","year":"2018","unstructured":"Nakajima K, Iwata H, Ogino H, Hattori Y, Hashimoto S, Nakanishi M, et al. Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer. Int J Clin Oncol. 2018;23:353\u201360.","journal-title":"Int J Clin Oncol"},{"key":"2027_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00066-017-1223-9","volume":"194","author":"S Hashimoto","year":"2018","unstructured":"Hashimoto S, Sugie C, Iwata H, Ogino H, Omachi C, Yasui K, et al. Recovery from sublethal damage and potentially lethal damage. Strahlenther Onkol. 2018;194:343\u201351.","journal-title":"Strahlenther Onkol"},{"key":"2027_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0360-3016(02)02754-2","volume":"53","author":"H Paganetti","year":"2002","unstructured":"Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loeffler JS, et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002;53:407\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2027_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijrobp.2016.01.017","volume":"95","author":"H Iwata","year":"2016","unstructured":"Iwata H, Ogino H, Hashimoto S, Yamada M, Shibata H, Yasui K, et al. Spot scanning and passive scattering proton therapy: relative biological effectiveness and oxygen enhancement ratio in cultured cells. Int J Radiat Oncol Biol Phys. 2016;95:95\u2013102.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2027_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/0284186X.2014.948060","volume":"54","author":"C Makita","year":"2015","unstructured":"Makita C, Nakamura T, Takada A, Takayama K, Suzuki M, Azami Y, et al. High-dose proton beam therapy for stage I non-small cell lung cancer: clinical outcomes and prognostic factors. Acta Oncol. 2015;54:307\u201314.","journal-title":"Acta Oncol"},{"key":"2027_CR21","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.cllc.2013.11.002","volume":"15","author":"A Kanemoto","year":"2014","unstructured":"Kanemoto A, Okumura T, Ishikawa H, Mizumoto M, Oshiro Y, Kurishima K, et al. Outcomes and prognostic factors for recurrence after high-dose proton beam therapy for centrally and peripherally located stage I non-small-cell lung cancer. Clin Lung Cancer. 2014;15:e7-12.","journal-title":"Clin Lung Cancer"},{"key":"2027_CR22","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/cncr.24998","volume":"116","author":"H Iwata","year":"2010","unstructured":"Iwata H, Murakami M, Demizu Y, Miyawaki D, Terashima K, Niwa Y, et al. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer. 2010;116:2476\u201385.","journal-title":"Cancer"},{"key":"2027_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1097\/JTO.0b013e318288ab02","volume":"8","author":"H Iwata","year":"2013","unstructured":"Iwata H, Demizu Y, Fujii O, Terashima K, Mima M, Niwa Y, et al. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a\u2013T2bN0M0) non-small-cell lung cancer. J Thorac Oncol. 2013;8:726\u201335.","journal-title":"J Thorac Oncol"},{"key":"2027_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.radonc.2015.05.014","volume":"115","author":"QN Nguyen","year":"2015","unstructured":"Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II\u2013III inoperable non-small cell lung cancer. Radiother Oncol. 2015;115:367\u201372.","journal-title":"Radiother Oncol"},{"key":"2027_CR25","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/jrr\/rru034","volume":"55","author":"Y Oshiro","year":"2014","unstructured":"Oshiro Y, Okumura T, Kurishima K, Homma S, Mizumoto M, Ishikawa H, et al. High-dose concurrent chemo-proton therapy for stage III NSCLC: preliminary results of a phase II study. J Radiat Res. 2014;55:959\u201365.","journal-title":"J Radiat Res"},{"key":"2027_CR26","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1002\/cncr.26080","volume":"117","author":"JY Chang","year":"2011","unstructured":"Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011;117:4707\u201313.","journal-title":"Cancer"},{"key":"2027_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/jrr\/rrv099","volume":"57","author":"K Ohta","year":"2016","unstructured":"Ohta K, Shimohira M, Murai T, Nishimura J, Iwata H, Ogino H, et al. Percutaneous fiducial marker placement prior to stereotactic body radiotherapy for malignant liver tumors: an initial experience. J Radiat Res. 2016;57:174\u20137.","journal-title":"J Radiat Res"},{"key":"2027_CR28","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/j.prro.2018.10.001","volume":"9","author":"S Hashimoto","year":"2019","unstructured":"Hashimoto S, Katsurada M, Muramatsu R, Asai K, Tanaka K, Hayashi K, et al. Effect of a device-free compressed shell fixation method on hepatic respiratory movement: analysis for respiratory amplitude of the liver and internal motions of a fiducial marker. Pract Radiat Oncol. 2019;9:e149\u201355.","journal-title":"Pract Radiat Oncol"},{"key":"2027_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"2027_CR30","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S0959-8049(97)00395-X","volume":"34","author":"K Kobayashi","year":"1998","unstructured":"Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S, et al. A cross-validation of the European Organization for Research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer. 1998;34:810\u20135.","journal-title":"Eur J Cancer"},{"key":"2027_CR31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","volume":"30A","author":"B Bergman","year":"1994","unstructured":"Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer. 1994;30A:635\u201342.","journal-title":"Eur J Cancer"},{"key":"2027_CR32","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","volume":"51","author":"S Fukuhara","year":"1998","unstructured":"Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol. 1998;51:1037\u201344.","journal-title":"J Clin Epidemiol"},{"key":"2027_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.canrad.2011.04.003","volume":"15","author":"V Gr\u00e9goire","year":"2011","unstructured":"Gr\u00e9goire V, Mackie TR. State of the art on dose prescription, reporting and recording in intensity-modulated radiation therapy (ICRU report No. 83). Cancer Radiother. 2011;15:555\u20139.","journal-title":"Cancer Radiother"},{"key":"2027_CR34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2027_CR35","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","volume":"17","author":"DS Ettinger","year":"2019","unstructured":"Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2019;17:1464\u201372.","journal-title":"J Natl Compr Canc Netw"},{"key":"2027_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.radonc.2017.08.026","volume":"125","author":"Y Tsurugai","year":"2017","unstructured":"Tsurugai Y, Takeda A, Sanuki N, Enomoto T, Kaneko T, Hara Y, et al. Stereotactic body radiotherapy for lung cancer patients with idiopathic interstitial pneumonias. Radiother Oncol. 2017;125:310\u20136.","journal-title":"Radiother Oncol"},{"key":"2027_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13014-016-0637-3","volume":"11","author":"T Ono","year":"2016","unstructured":"Ono T, Hareyama M, Nakamura T, Kimura K, Hayashi Y, Azami Y, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience. Radiat Oncol. 2016;11:56.","journal-title":"Radiat Oncol"},{"key":"2027_CR38","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.ijrobp.2010.05.016","volume":"79","author":"N Kadoya","year":"2011","unstructured":"Kadoya N, Obata Y, Kato T, Kagiya M, Nakamura T, Tomoda T, et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;79:1225\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2027_CR39","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.rmed.2014.07.020","volume":"108","author":"T Lee","year":"2014","unstructured":"Lee T, Park JY, Lee HY, Cho YJ, Yoon H, Lee JH, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med. 2014;108:1549\u201355.","journal-title":"Respir Med"},{"key":"2027_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1378\/chest.14-0359","volume":"147","author":"S Tomassetti","year":"2015","unstructured":"Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147:157\u201364.","journal-title":"Chest"},{"key":"2027_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1510\/icvts.2010.260067","volume":"13","author":"M Kanzaki","year":"2011","unstructured":"Kanzaki M, Kikkawa T, Maeda H, Kondo M, Isaka T, Shimizu T, et al. Acute exacerbation of idiopathic interstitial pneumonias after surgical resection of lung cancer. Interact Cardiovasc Thorac Surg. 2011;13:16\u201320.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2027_CR42","first-page":"340","volume":"10","author":"K Koizumi","year":"2004","unstructured":"Koizumi K, Hirata T, Hirai K, Mikami I, Okada D, Yamagishi S, et al. Surgical treatment of lung cancer combined with interstitial pneumonia: the effect of surgical approach on postoperative acute exacerbation. Ann Thorac Cardiovasc Surg. 2004;10:340\u20136.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"2027_CR43","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/1471-2407-14-508","volume":"14","author":"M Kato","year":"2014","unstructured":"Kato M, Shukuya T, Takahashi F, Mori K, Suina K, Asao T, et al. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer. 2014;14:508.","journal-title":"BMC Cancer"},{"key":"2027_CR44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.lungcan.2013.08.024","volume":"82","author":"S Yamaguchi","year":"2013","unstructured":"Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82:260\u20135.","journal-title":"Lung Cancer"},{"key":"2027_CR45","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/JTO.0000000000000525","volume":"10","author":"Y Shibamoto","year":"2015","unstructured":"Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Miyakawa A, Murai T, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol. 2015;10:960\u20134.","journal-title":"J Thorac Oncol"},{"key":"2027_CR46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ijrobp.2015.07.2278","volume":"93","author":"Y Nagata","year":"2015","unstructured":"Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93:989\u201396.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2027_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2004.02.015","volume":"71","author":"G Rodrigues","year":"2004","unstructured":"Rodrigues G, Lock M, D\u2019Souza D, Yu E, van Dyk J. Prediction of radiation pneumonitis by dose\u2013volume histogram parameters in lung cancer\u2014a systematic review. Radiother Oncol. 2004;71:127\u201338.","journal-title":"Radiother Oncol"},{"key":"2027_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1148\/radiol.2351040248","volume":"235","author":"HK Tae","year":"2005","unstructured":"Tae HK, Kwan HC, Hong RP, Jin SL, Jae IZ, Dae HL, et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology. 2005;235:208\u201315.","journal-title":"Radiology"},{"key":"2027_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5603\/ARM.a2019.0003","volume":"87","author":"E Szeliga","year":"2019","unstructured":"Szeliga E, Czenczek-Lewandowska E, Kontek A, Wolan-Nieroda A, Guzik A, Walicka-Cupry\u015b K. Evaluation of the quality of life after surgical removal of lung cancer. Adv Respir Med. 2019;87:14\u20139.","journal-title":"Adv Respir Med"},{"key":"2027_CR50","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1002\/cncr.29682","volume":"121","author":"M Koller","year":"2015","unstructured":"Koller M, Warncke S, Hjermstad MJ, Arraras J, Pompili C, Harle A, et al. Use of the lung cancer-specific quality of life questionnaire EORTC QLQ-LC13 in clinical trials: a systematic review of the literature 20 years after its development. Cancer. 2015;121:4300\u201323.","journal-title":"Cancer"},{"key":"2027_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/JTO.0b013e3182340abb","volume":"7","author":"A M\u00f6ller","year":"2012","unstructured":"M\u00f6ller A, Sartipy U. Associations between changes in quality of life and survival after lung cancer surgery. J Thorac Oncol. 2012;7:183\u20137.","journal-title":"J Thorac Oncol"},{"key":"2027_CR52","doi-asserted-by":"publisher","first-page":"594590","DOI":"10.3389\/fonc.2020.594590","volume":"10","author":"A Sardaro","year":"2020","unstructured":"Sardaro A, McDonald F, Bardoscia L, Lavrenkov K, Singh S, Ashley S, et al. Dyspnea in patients receiving radical radiotherapy for non-small cell lung cancer: a prospective study. Front Oncol. 2020;10:594590.","journal-title":"Front Oncol"},{"key":"2027_CR53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.lungcan.2020.03.023","volume":"145","author":"R Thomas","year":"2020","unstructured":"Thomas R, Chen Y-H, Hatabu H, Mak RH, Nishino M. Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: imaging predictors for clinical severity and outcome. Lung Cancer. 2020;145:132\u20139.","journal-title":"Lung Cancer"},{"key":"2027_CR54","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ijrobp.2017.03.010","volume":"98","author":"H Chen","year":"2017","unstructured":"Chen H, Senan S, Nossent EJ, Boldt RG, Warner A, Palma DA, et al. Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: a systematic review. Int J Radiat Oncol Biol Phys. 2017;98:622\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2027_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","volume":"111","author":"D Fujimoto","year":"2017","unstructured":"Fujimoto D, Morimoto T, Ito J, Sato Y, Ito M, Teraoka S, et al. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer. 2017;111:1\u20135.","journal-title":"Lung Cancer"},{"key":"2027_CR56","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","volume":"21","author":"J Sul","year":"2016","unstructured":"Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist. 2016;21:643\u201350.","journal-title":"Oncologist"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02027-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02027-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02027-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T02:36:42Z","timestamp":1700361402000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02027-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02027-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the institutional review board of Nagoya City Hospital (20\u201304-327-07, August 5th, 2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}